SARS-CoV-2 inactivated whole virion antigens (SARS-CoV-2 IVV)

SARS-CoV-2 inactivated whole virion antigens comprise the full suite of structural proteins from the virus, including the Spike, Envelope, Membrane, and Nucleocapsid proteins, which have been rendered non-replicative through chemical inactivation (Science, 2020). This antigenic complex is used in traditional vaccine platforms to mimic the native virus structure, allowing the host immune system to recognize and mount a response against multiple viral components (The Lancet Infectious Diseases, 2021). Unlike subunit vaccines that target only the Spike protein, the inclusion of the Nucleocapsid and other proteins may provide broader T-cell recognition and resilience against variants (Nature, 2021). Upon administration, these antigens are internalized by professional antigen-presenting cells, such as dendritic cells, and presented to B and T lymphocytes (Cell, 2020). This process leads to the development of immunological memory and the production of neutralizing antibodies that block viral entry into host cells (Nature Communications, 2020). This approach has been widely utilized in global vaccination campaigns, particularly with vaccines like CoronaVac and Covaxin, due to its established safety profile and standard cold-chain storage requirements (WHO, 2022). However, the use of whole virions necessitates stringent quality control to ensure complete inactivation and to monitor for rare immune-mediated complications like vaccine-associated enhanced respiratory disease (Journal of Virology, 2021). The target remains a cornerstone of global health efforts to provide accessible and effective immunization against COVID-19 (The Lancet, 2021).

Other names

Inactivated SARS-CoV-2Whole-virion inactivated SARS-CoV-2Inactivated COVID-19 vaccine antigenSARS-CoV-2 inactivated virus

Inactivated whole virions act as a complex of antigens that are processed by antigen-presenting cells to induce a broad-spectrum immune response. They present multiple structural proteins (S, N, M, E) to the immune system, triggering the production of neutralizing antibodies and activating T-cell mediated immunity to prevent viral entry and replication (Science, 2020; The Lancet, 2021).